View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Appian To Announce Third Quarter 2025 Financial Results on November 6,...

Appian To Announce Third Quarter 2025 Financial Results on November 6, 2025 MCLEAN, Va., Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: APPN) today announced that it will release financial results for the third quarter ended September 30, 2025 before the U.S. financial markets open on Thursday, November 6, 2025. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can join the call, us...

 PRESS RELEASE

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicine...

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual...

 PRESS RELEASE

Tenaya Therapeutics to Participate in Upcoming October Investor Confer...

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6Time: 8:00 AM MT – 9:00 A...

 PRESS RELEASE

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rul...

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 202,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exerci...

 PRESS RELEASE

HVIP Is Back: Here’s What California Fleets Need to Know (And Why It M...

HVIP Is Back: Here’s What California Fleets Need to Know (And Why It Matters Now) Xos, Inc. explains how it helps California fleets navigate HVIP and maximize funding for electric trucks LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: XOS) - The Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) is officially back, and California fleets have a major opportunity to secure funding for electric trucks. Depending on fleet size, incentives range from $85,000 to $160,000 per Class 6 vehicle, with up to 20 vouchers available per fleet. On September 9, 2025, the C...

 PRESS RELEASE

Windrose and Xos Partner to Deliver Game-Changing Charging Access for ...

Windrose and Xos Partner to Deliver Game-Changing Charging Access for Class 8 Electric Fleets LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Windrose, manufacturer of one of the lightest and longest-range electric Class 8 trucks in the world, is partnering with Xos (NASDAQ: XOS), a leading provider of mobile charging solutions, to bring powerful, scalable charging to fleet operators across the United States and international markets. Windrose's Class 8 electric truck is engineered from the ground up for global deployment across 6 markets: North America, Europe, South America, Oceania, A...

 PRESS RELEASE

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual G...

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET. The live...

 PRESS RELEASE

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural Histor...

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes SOUTH SAN FRANCIS...

 PRESS RELEASE

Xos, Inc. Appoints Automotive Veteran John Smith to its Board of Direc...

Xos, Inc. Appoints Automotive Veteran John Smith to its Board of Directors Former General Motors Group Vice President brings decades of global automotive, strategy, and governance experience as Xos scales MDXT and charging solutions LOS ANGELES, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Xos, Inc., a leading manufacturer of medium‑duty electric vehicles and mobile charging solutions, today announced that John F Smith has been appointed to the Company’s Board of Directors, effective August 18, 2025. With Mr. Smith’s appointment, the Board has increased from eight to nine directors. Mr. Smith has ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Xos Breaks the $100K Barrier for High-Powered Mobile Charging with New...

Xos Breaks the $100K Barrier for High-Powered Mobile Charging with New Hub Approved for $110,000 CORE Incentive LOS ANGELES, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) announced today that the newest version of its mobile charging unit, the Xos Hub™, has been approved for California’s Clean Off-Road Equipment (CORE) Voucher Incentive Project, making it eligible for a . This groundbreaking approval means the Xos Hub is now available for under $100,000, less than half the cost of many equivalent DC fast charging systems, which often exceed $200,000. The result is a major le...

 PRESS RELEASE

Xos Hits New Milestones in Q2 2025 with Highest Revenue and Deliveries...

Xos Hits New Milestones in Q2 2025 with Highest Revenue and Deliveries in the Company’s History Reduced year-over-year operating expenses by $4.7 million and posted lowest operating loss as a public company in the second quarter of 2025 Generated positive net cash provided by operating activities of $4.6 million in the second quarter of 2025 LOS ANGELES, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leader in electric commercial vehicles and mobile charging solutions, today announced a breakout quarter by a number of measures. In t...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annua...

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may be a...

 PRESS RELEASE

Appian Announces Second Quarter 2025 Financial Results

Appian Announces Second Quarter 2025 Financial Results Second quarter cloud subscriptions revenue increased 21% year-over-year to $106.9 million Second quarter total revenue increased 17% year-over-year to $170.6 million MCLEAN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the second quarter ended June 30, 2025. “Appian AI drove strong financial results in the second quarter of 2025, with higher prices and a larger pipeline,” said Matt Calkins, CEO & Founder. Second Quarter 2025 Financial Highlights: Revenue: Cloud subscriptions r...

 PRESS RELEASE

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and ...

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Following DSMB Recommendation to Dose Escalate and Expand Data Readouts from Both TN-201 and TN-401 Clinical Programs Planned for the Fourth Quarter of 2025 Cash Runway into Second Half of 2026 SO...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 5, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Appian To Participate in Upcoming Investor Conferences

Appian To Participate in Upcoming Investor Conferences MCLEAN, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN), the leading platform for AI process automation, announced today that management will be presenting and hosting meetings with institutional investors at the following upcoming conferences: Keybanc Technology Leadership ForumMonday August 11, 2025A fireside chat is scheduled for 2:00pm Mountain Time and will be webcast live at the following link: Citi Global TMT ConferenceWednesday September 3, 2025A fireside chat is scheduled for 12:50pm Eastern Time and will ...

 PRESS RELEASE

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Adva...

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE™-1 Phase 1b Clinical Trial of TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Initial Cohort 1 Data for TN-401 and Enrollment of Additional Patients in Bo...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch